Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “KLH-2109 Placebo: for 24 weeks(PO, QD) Leurprorelin acetate Placebo: 1.88mg or 3.75mg , Once every 4 weeks, subcutaneous injection”In the company’s words, NCT07378098 on ClinicalTrials.gov
- Tested for
- Menorrhagia, Uterine Fibroids
- Main trialPhase 3
- “The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus. The primary objectives of this trial were to answer the following questions: * Does KLH-2109 lower the amount of menstrual bleeding? * Does KLH-2109 reduce menstrual bleeding? * Is KLH-2109 safe for participants to use? Investigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective.…”In the company’s words, NCT07378098 on ClinicalTrials.gov
Other drugs for Uterine Fibroids
Coming up1
- 31 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Mar 2028 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026